Astellas Licenses Antibody Technology From Kyowa Hakko Kirin
This article was originally published in PharmAsia News
Kyowa Hakko Kirin U.S. subsidiary Biowa announced a licensing agreement with Astellas subsidiary Agensys. Biowa will provide proprietary Potelligent antibody technology to Agensys in exchange for a licensing fee. California-based Agensys is a biopharmaceutical venture firm focusing on antibody cancer drug development. The company was acquired by Astellas in 2007. (Click here for more - Japanese language
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.